To utilize the capabilities and proven scientific genius of Prof. Youdim, his ability to access big pharma corporate executives, investors and KOLs, and the team’s business knowhow and track record for success in promoting science-based startups, towards the development of successful companies in the pharma and diagnostic fields.
Yokneam, Israel – Curewize, Curewize Successfully Completed Clinical Trial on Lab Test Revealing Acute Lymphoblastic Leukemia Patients’ Optimal Treatment Regimen
Yokneam, Israel, November 17, 2016 – Curewize, today announced that they will be presenting Results at 58th ASH Annual Meeting & Exposition, September 3rd – 6th, 2016, San Diego, CA, USA.
Yokneam, Israel, November 17, 2016 – Bioshai, expects to begin commercializing its unique assay in 2017, applying for CE clearance in Europe. You can read more about it in BIOSHAI’S article published in Israel21c.
Yokneam, Israel, August 29, 2016 – Youdim Pharmaceuticals’ subsidiaries, GlaucoPharm, N2B and Bioshai, today announced that they will be presenting at the Sachs Associates convention for partnering and investment, September 27th – 28th, 2016, Congress Center Basel, Switzerland.
Yokneam, Israel, August 26, 2016 – GlaucoPharm, a pharmaceutical R&D company developing a proprietary compound, TG-46, for the treatment of glaucoma, has been granted a third year research budget by the OCS – Office of the Chief Scientist of Israel (Reshut Hachadshanut).
Yokneam, Israel, August 16, 2016 – Youdim Pharmaceuticals today announced that it will be presenting at the Life Sciences Baltics forum, September 14-15, 2016, Lithuanian Exhibition and Congress Center LITEXPO, Vilnius, Lithuania. The company’s management is set to meet Lithuanian government officials to discuss partnering and cooperation.
Yokneam, Israel, August 15, 2016 – N2B Ltd. announced today the recruitment of Dr. Hadile Ounallah-Saad, a researcher from Haifa University with a specialty in Alzheimer’s disease, to lead its research. N2B is a pharmaceutical drug repositioning company developing medical care for depression associated with early Parkinson’s disease (PD), through the proprietary reformulation of existing drugs.
Yokneam, Israel, August 1, 2016 – Youdim Pharmaceuticals named as its Intellectual Property Strategy Director Israeli patent attorney and US patent agent Avraham Hermon. Hermon is an expert in creating patent portfolios and IP strategy for pharmaceutical and biotech companies, and former Senior Manager at Teva’s Global Patent Group.
Yokneam, Israel, April 20, 2016 – Bioshai Ltd., an emerging diagnostic company focused on the development of diagnostic biomarker kits for Parkinson’s disease, announced today that it has been chosen to display its achievements at Israel’s Biomed conference in May 2016.
Yokneam, Israel, April 14, 2016 – Curewize Ltd., a clinical research and commercialization company aiming to advance the personalized treatment of cancers common to children, adolescents and young adults, announced today that it will provide an overview of its work at Israel’s Biomed conference in May 2016.
Yokneam, Israel, April 1, 2016 – Youdim Pharmaceuticals. Alon Yaar, DVM, MBA, an industry veteran and co-founder and former CEO of NeuroDerm (Nasdaq: NDRM) will now assume the role of CEO of Youdim Pharmaceuticals and join the company’s Board of Directors. Prof. Eliahu Heldman, co-founder of NeuroDerm (Nasdaq: NDRM), shall join the company’s Board of Directors and become a member of its Scientific Advisory Board.
Yokneam, Israel, February 1, 2016 – Youdim Pharmaceuticals. Nir Peles, CPA, MBA, MA (Law), former CFO at BluePhoenix Solutions (NASDAQ: BPHX) and VP Finance at Alcobra Pharma (NASDAQ: ADHD) will take the role of CFO.